bioRxiv · 10.1101/2024.02.23.581752
Extended blood stage sensitivity profiles of Plasmodium vivax to doxycycline and tafenoquine using Plasmodium cynomolgi as a model
Abstract
Testing Plasmodium vivax antimicrobial sensitivity is limited to ex vivo schizont maturation assays, which precludes determining the IC50s of delayed action antimalarials such as doxycycline. Using Plasmodium cynomolgi as a model for P. vivax, we determined the physiologically significant delayed death effect induced by doxycycline (IC50(96h), 1401 {+/-} 607 nM). As expected, IC50(96 h) to chloroquine (20.4 nM), piperaquine (12.6 {micro}M) and tafenoquine (1424 nM) were not affected by extended exposure.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Christensen, P., Cinzah, R., Suwanarusk, R., Chua, A. C. Y., Kaneko, O., Kyle, D. E., Aung, H. L., Matheson, J., Bifani, P., Renia, L., Cook, G. M., Snounou, G., Russell, B. M.. 2024-02-28. Extended blood stage sensitivity profiles of Plasmodium vivax to doxycycline and tafenoquine using Plasmodium cynomolgi as a model. https://doi.org/10.1101/2024.02.23.581752
Cite the original work for its findings. Save a collection to share your selection of sources.